1. Home
  2. ICHR vs CRVS Comparison

ICHR vs CRVS Comparison

Compare ICHR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ichor Holdings

ICHR

Ichor Holdings

HOLD

Current Price

$29.78

Market Cap

605.5M

Sector

Technology

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$8.05

Market Cap

546.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICHR
CRVS
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
605.5M
546.7M
IPO Year
2016
2016

Fundamental Metrics

Financial Performance
Metric
ICHR
CRVS
Price
$29.78
$8.05
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$27.50
$13.75
AVG Volume (30 Days)
795.7K
1.6M
Earning Date
02-09-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$957,337,000.00
N/A
Revenue This Year
$13.48
N/A
Revenue Next Year
$5.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.86
N/A
52 Week Low
$13.12
$2.54
52 Week High
$35.56
$9.60

Technical Indicators

Market Signals
Indicator
ICHR
CRVS
Relative Strength Index (RSI) 84.60 58.46
Support Level $21.44 $6.46
Resistance Level $31.43 $7.18
Average True Range (ATR) 1.77 0.50
MACD 0.90 0.08
Stochastic Oscillator 87.41 93.26

Price Performance

Historical Comparison
ICHR
CRVS

About ICHR Ichor Holdings

Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, Singapore, Europe, and Others, of which a majority of the revenue is generated from Singapore.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: